海外の治験の状況「前立腺癌」での検索結果
242件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Authorised
- Randomized adjuvant phase III trial of six cycles of docetaxel+hormonal treatment versus hormonal treatment in patients with intermediate or high-risk prostate cancer treated with radical radiotherapy. “AdRad” Scandinavian Prostate Cancer Group Trial 13 - AdRad
- Intermediate or high-risk prostate cancer treated with radical radiotherapy MedDRA version: 8.1 Level: PT Classification code 10060862 Term: Prostate cancer
- Finland, Ireland, Sweden
- 2006-10-04
Authorised
- Detection and staging of bone metastases in prostate cancer, not yet been treated with hormones, using labelled testosterone in PET/CT.
- Hormone naive prostate cancer, metastasized to bone (2 or more bone metastases).;Therapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12]
- Netherlands
- 2013-06-19
Authorised
- A study of the safety, pharmacokinetics and effects of seviteronel in men with prostate cancer that does not respond to hormone treatment
- Castration-resistant prostate cancer (CRPC) MedDRA version: 20.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Greece, Switzerland, United Kingdom, United States
- 2011-08-31
Authorised
- Clinical trial to evaluate the safety and immune activation of DCVAC/PCa and ONCOS-102 in men with metastatic prostate cancer.
- advanced metastatic castration-resistant prostate cancer br>MedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Czech Republic
- 2016-06-21
Authorised
- Single site, phase II, double blind, randomised, placebo controlled study of the effect of dutasteride (Avodart)0.5 mg on the volume and characteristics of prostate cancer, as assessed by multifunctional magnetic resonance imaging (MRI) in a low risk prostate cancer population - MRI in Primary Prostate cancer after Exposure to Dutasteride (MAPPED)
- Low risk prostate cancer br>MedDRA version: 14.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
- United Kingdom
- 2010-03-15
Authorised
- A clinical trial to investigate the safety and effect of a drug called AT13387 on its own or given with another drug Abiraterone Acetate on certain types of Prostate Cancer that does not respond to treatment with Abiraterone alone.
- Castration-Resistant Prostate Cancer (CRPC) MedDRA version: 14.1 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Canada, United Kingdom, United States
- 2012-05-25
Authorised
- The aim of the study is to see if a new drug, enzalutamide, can improve outcomes for patients with metastatic prostate cancer compared with current treatment.This is a randomised controlled study trial which means that half the participants on the trial study will get enzalutamide and the other half will get current standard of care. All participants will receive active treatment for their cancer.
- Metastatic Prostate Cancer br>MedDRA version: 20.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Canada, France, Ireland, New Zealand, Poland, United Kingdom, United States
- 2014-11-21
Authorised
- CHemotherapy plus Enzalutamide In first line therapy for castration Resistant prOstate caNcer
- castration Resistant prOstate caNcer;Therapeutic area: Diseases [C] - Cancer [C04]
- Italy
- 2014-06-20
Authorised
- Is it possible to personalize therapy with Enzalutamide by monitoring biomarkers and blood levels, in patients with metastatic prostate cancer?
- Metastatic Castration Resistant Prostate Cancer (mCRPC) MedDRA version: 19.1 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 19.1 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 19.1 Level: PT Classification code 10062904 Term: Hormone-refractory prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04];Metastatic Castration Resistant Prostate Cancer (mCRPC) MedDRA version: 19.1 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 19.1 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 19.1 Level: PT Classification code 10062904 Term: Hormone-refractory prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04];Metastatic Castration Resistant Prostate Cancer (mCRPC) MedDRA version: 19.1 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 19.1 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 19.1 Level: PT Classification code 10062904 Term: Hormone-refractory prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Netherlands
- 2015-04-21
Authorised
- PET/MRI in patients with suspected prostate cancer
- Clinical suspected prostate cancer br>MedDRA version: 20.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
- Austria
- 2015-03-04
